| sinespace

O test the specificity of antibodies for cannabinoid receptors. Hippocampus 2012, 22:643?44. 62. Atwood

Revision as of 07:50, 18 April 2019 by Chime77gold (Talk | contribs)

Jump to: navigation, search

Thus, ATB-346 could represent an exciting approach for the management of secondary harm following CNS illnesses, counteracting behavioral adjustments and inflammatory approach. Keywords and phrases: Brain trauma, Hydrogen Royal Jelly acidSolvent sulfide, Neurotrophic element, Inflammation, Motor recovery, Infarct area, Infarct volume, Nitrosative tension, Astrogliosis, Neuroprotection* Correspondence: Equal contributors 1 Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy three Manchester Biomedical Research Centre,.O test the specificity of antibodies for cannabinoid receptors. Hippocampus 2012, 22:643?44. 62. Atwood BK, Mackie K: CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010, 160:467?79. 63. Lopez-Rodriguez AB, Siopi E, Finn DP, Marchand-Leroux C, Garcia-Segura LM, Jafarian-Tehrani M, Viveros MP: CB1 and CB2 cannabinoid receptor antagonists avert minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb Cortex 2013. doi:ten.1093/cercor/ bhtdoi:10.1186/s12974-014-0191-6 Cite this article as: Amenta et al.: Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. Journal of Neuroinflammation 2014 11:191. Campolo et al. PubMed ID: Journal of Neuroinflammation 2014, 11:196 OF NEUROINFLAMMATIONRESEARCHOpen AccessHydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in miceMichela Campolo1, Emanuela Esposito1, Akbar Ahmad1, Rosanna Di Paola1, Irene Paterniti1, Marika Cordaro1, Giuseppe Bruschetta1, John L Wallace2 and Salvatore Cuzzocrea1,3*AbstractBackground: Traumatic brain injury (TBI) induces secondary injury mechanisms, like dynamic interplay involving ischemic, inflammatory and cytotoxic processes. We recently reported that administration of ATB-346 (2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester), a hydrogen sulfide-releasing cyclooxygenase inhibitor, showed marked helpful effects in an animal PubMed ID: model of spinal cord injury, considerably enhancing recovery of motor function and minimizing the secondary inflammation and tissue injury. Procedures: Right here we evaluated the neuroprotective prospective of ATB-346, a hydrogen sulfide-releasing derivative of naproxen, applying the controlled cortical influence (CCI) injury model in mice, among by far the most common models of TBI. In addition, the aim on the present study was to meticulously investigate molecular pathways and subtypes of glial cells involved inside the protective impact of ATB-346 on inflammatory reaction connected with an experimental model of TBI. In these studies, TBI was induced in mice by CCI and mice have been orally administered ATB-346, naproxen (both at 30 mol/kg) or vehicle (dimethylsulfoxide:1 carboxymethylcellulose [5:95] suspension) one particular and six hours immediately after brain trauma and once each day for ten days. Benefits: Results revealed that ATB-346 attenuated TBI-induced brain edema, suppressed TBI-induced neural cell death and enhanced neurological function. ATB-346 also drastically decreased the severity of inflammation and restored neurotrophic variables that characterized the secondary events of TBI. Conclusions: These data demonstrate that ATB-346 may be efficacious inside a TBI animal model by reducing the secondary inflammation and tissue injury. As a result, ATB-346 could represent an interesting method for the management of secondary harm following CNS diseases, counteracting behavioral alterations and inflammatory course of action.